Financing Agreements in the Biotechnology Industry

28 Contracts & Agreements

Browse by Company

Adhera Therapeutics, Inc. (1 contract)
Athenex, Inc. (1)
BIOCRYST PHARMACEUTICALS INC (2)
Biohaven Pharmaceutical Holding Co Ltd. (2)
BioXcel Therapeutics, Inc. (1)
Blueprint Medicines Corp (1)
Clovis Oncology, Inc. (2)
CTI BIOPHARMA CORP (6)
Environmental Impact Acquisition Corp (1)
Gritstone Oncology, Inc. (0)
Intrinsic Medicine, Inc. (1)
Karyopharm Therapeutics Inc. (1)
PREMIER BIOMEDICAL INC (1)
Propanc Biopharma, Inc. (1)
REXAHN PHARMACEUTICALS, INC. (2)
Rich Pharmaceuticals, Inc. (1)
Spectrum Pharmaceuticals, Inc. (1)
Sunshine Biopharma, Inc (2)
WINDTREE THERAPEUTICS INC (1)

Recent Contracts

First Amendment to Financing Agreement dated as of May 22, 2023 by and among Blueprint Medicines Corporation, the lenders party thereto, and TAO Talents LLC, as Administrative... (Blueprint Medicines Corp, Filed With SEC on May 25, 2023)
First Amendment to Revenue Interest Financing Agreement, dated August 4, 2022, by and between the Company, the purchasers party thereto and Oaktree Fund Administration, LLC, as... (BioXcel Therapeutics, Inc., Filed With SEC on May 9, 2023)
Secured Superpriority Debtor-In-Possession Financing Agreement, dated as of January 6, 2023, by and among the Company, as borrower, Clovis Ireland and Clovis UK, as guarantors,... (Clovis Oncology, Inc., Filed With SEC on January 12, 2023)
Omnibus Amendment #1 to Financing Agreements by and between the Registrant and the investor who is a signatory thereto (Intrinsic Medicine, Inc., Filed With SEC on April 8, 2022)
Amendment No. 4 to Financing Agreement, dated as of December 28, 2021, by and between Biohaven Pharmaceuticals Holding Company Ltd., Biohaven Pharmaceuticals, Inc., the guarantors... (Biohaven Pharmaceutical Holding Co Ltd., Filed With SEC on February 25, 2022)
Amendment No. 3 and Limited Consent to Financing Agreement, dated November 9, 2021, by and between Biohaven Pharmaceuticals Holding Company Ltd., Biohaven Pharmaceuticals, Inc.,... (Biohaven Pharmaceutical Holding Co Ltd., Filed With SEC on November 12, 2021)
Master Equipment Financing Agreement, dated March 29, 2021, by and between Trinity Capital Inc. and GreenLight Biosciences, Inc (Environmental Impact Acquisition Corp, Filed With SEC on September 7, 2021)
Project Financing Agreement, dated August 12, 2020, by and between Windtree and Lees Pharmaceutical (HK) Ltd (WINDTREE THERAPEUTICS INC, Filed With SEC on November 16, 2020)
Financing Agreement with RB Capital Partners, Inc (Sunshine Biopharma, Inc, Filed With SEC on September 15, 2020)
Revenue Interest Financing Agreement (Athenex, Inc., Filed With SEC on August 6, 2020)
Form of Financing Lock-Up Agreement, by and among Rexahn, Ocuphire, and the investors party thereto (REXAHN PHARMACEUTICALS, INC., Filed With SEC on July 1, 2020)
Form of Financing Lock-Up Agreement, by and among Rexahn, Ocuphire, and the investors party thereto (REXAHN PHARMACEUTICALS, INC., Filed With SEC on June 19, 2020)
Technology Acquisition and Financing Agreement dated May 8, 2020 (PREMIER BIOMEDICAL INC, Filed With SEC on May 14, 2020)
Revenue Interest Financing Agreement, dated September 14, 2019, between the Registrant and HealthCare Royalty Partners III, L.P, and HealthCare Royalty Partners IV, L.P (Karyopharm Therapeutics Inc., Filed With SEC on November 4, 2019)
Financing Agreement, dated as of May 1, 2019 among Clovis Oncology, Inc. (the Company), certain subsidiaries of the Company named therein, as Guarantors, the Lenders from time to... (Clovis Oncology, Inc., Filed With SEC on May 2, 2019)
Equity Financing Agreement dated September 10, 2018 by and between Sunshine Biopharma, Inc. and GHS Investments, LLC (Sunshine Biopharma, Inc, Filed With SEC on September 14, 2018)
Equity Financing Agreement dated February 22, 2017 with GHS Investments, LLC (Rich Pharmaceuticals, Inc., Filed With SEC on February 27, 2017)
EQUITY FINANCING AGREEMENT (Propanc Biopharma, Inc., Filed With SEC on December 7, 2016)
Convertible Preferred Financing (Adhera Therapeutics, Inc., Filed With SEC on February 24, 2014)
SIDE AGREEMENT TO INVESTOR FINANCING AGREEMENT (BIOCRYST PHARMACEUTICALS INC, Filed With SEC on October 22, 2012)
INVESTOR FINANCING AGREEMENT by and among BIOCRYST PHARMACEUTICALS, INC. and THE INVESTORS LISTED ON SCHEDULE 1 Dated as of October 17, 2012 TABLE OF CONTENTS (BIOCRYST PHARMACEUTICALS INC, Filed With SEC on October 22, 2012)
AMENDMENT NO. 3 TO THE STEP-UP EQUITY FINANCING AGREEMENT (CTI BIOPHARMA CORP, Filed With SEC on December 21, 2006)
AMENDMENT NO. 2 TO THE STEP-UP EQUITY FINANCING AGREEMENT (CTI BIOPHARMA CORP, Filed With SEC on October 5, 2006)
AMENDMENT NO. 1 TO THE STEP-UP EQUITY FINANCING AGREEMENT (CTI BIOPHARMA CORP, Filed With SEC on August 3, 2006)
STEP-UP EQUITY FINANCING AGREEMENT Dated June 21, 2006 (CTI BIOPHARMA CORP, Filed With SEC on June 23, 2006)
Recapitalized the Company by securing over $55 million in equity financing (Spectrum Pharmaceuticals, Inc., Filed With SEC on March 15, 2005)
[CONFIDENTIAL TREATMENT REQUESTED] FINANCING AGREEMENT (CTI BIOPHARMA CORP, Filed With SEC on March 4, 2005)
[CONFIDENTIAL TREATMENT REQUESTED] FINANCING AGREEMENT (CTI BIOPHARMA CORP, Filed With SEC on December 23, 2004)